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The tumor-promoting arm of transforming growth factor beta (TGF-) receptor signaling contributes to advanced cancer pro-
gression and is considered a master regulator of breast cancer metastasis. In mammals, there are six distinct members in the 
tumor-necrosis factor receptor (TNFR)-associated factor (TRAF) family (TRAF1–TRAF6), with the function of TRAF4 not 
being extensively studied in the past decade. Although numerous studies have suggested that there is elevated TRAF4 expres-
sion in human cancer, it is still unknown in which oncogenic pathway TRAF4 is mainly implicated. This review highlights 
TGF--induced SMAD-dependent signaling and non-SMAD signaling as the major pathways regulated by TRAF4 involved in 
breast cancer metastasis. 
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Transforming growth factor beta (TGF-) receptor signaling 
drives cancer metastasis, and the stability and membrane 
localization of its receptor is an important determinant in 
controlling the intensity and duration of TGF-β signaling. A 
genome-wide cDNA screen identified multiple important 
positive regulators of TGF-β-SMAD signaling [1–3]. 
Among them, a distant tumor-necrosis factor receptor 
(TNFR)-associated factor (TRAF) family member, TRAF4, 
is of interest as it could target different substrates to play 
positive roles in both SMAD-dependent and SMAD-   
independent TGF-β signaling. This apparently contributes 
to tumor cell migration. Importantly, TRAF4 gene copy 
number is increased in multiple cancer types and amplified 
the most in breast cancer patients. Variations in TRAF4 
expression accordingly modulate signaling readout and also 
TGF-β promoted phenotypes such as epithelial to mesen-
chymal transition (EMT) and tumor cell invasion and me-
tastasis. 
In vivo experiments involving established animal metas-
tasis models have verified the critical role that TRAF4 plays, 
and analyses of human patient samples further confirmed 
that TRAF4 correlates with poor prognosis. In this short 
review, we introduce both the background and work in pro-
gress on TRAF4-regulated TGF-β receptor signaling. We 
propose a working model of TRAF4 and highlight its criti-
cal role in controlling breast cancer metastasis. 
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1  TRAF4, an unusual TRAF family member 
The TRAF family consists of six members. Except for 
TRAF4, all other TRAFs were identified in a yeast 
two-hybrid screen using cytoplasmic domains from various 
members of the TNFR family [4]. Since the original study 
that identified TRAF1 and TRAF2 as the first members 
associating with TNFR2, the following work has provided 
strong evidence that TRAF2, TRAF3, TRAF5 and TRAF6 
are all involved in either canonical or alternative nuclear 
factor-κB (NF-κB) activation. (For the distinct role of these 
TRAFs in NF-κB signaling pathways, we refer the reader to 
an excellent review [4].) 
While later studies verified that TRAF1, TRAF2, TRAF3, 
TRAF5 and TRAF6 acted as adaptor proteins for various 
cell surface TNFRs and interleukin-1/Toll-like receptors 
(IL-1R/TLR) to mediate activation of NF-κB and activator 
protein 1 (AP1), it has not yet been demonstrated that 
TRAF4 functions in a similar manner [4,5]. Although all 
TRAF proteins share largely the same structure, such as an 
N-terminal RING finger domain, a middle zinc finger do-
main (not in TRAF1) and a conserved C-terminal TRAF 
domain, simplified in a comparison between TRAF4 and 
TRAF6 (Figure 1), TRAF4 seems to be unique as it is the 
only member that has seven zinc finger repeats (TRAF2, 
TRAF3, TRAF5 and TRAF6 contain five zinc finger re-
peats) [4]. Functionally distinct from other TRAFs that are 
mainly involved in the immune system [6,7], TRAF4 does 
not seem to play a role in the immune system as no immu-
nological defects have been identified in mice lacking 
TRAF4 [8,9]. 
2  TRAF4, an amplified gene in breast cancer 
As a RING domain-containing E3 ligase, TRAF4 was orig-
inally identified in a differential expression screen using a 
cDNA library of breast cancer-derived metastatic lymph 
nodes [10]. Further study showed that TRAF4 overexpres-
sion was a common characteristic of human carcinomas 
[11]. This is likely due to amplification or gain of gene 
copies in cancer. The TRAF4 gene, which is located in an 
amplified region of chromosome, is amplified in breast 
cancer and this is correlated with ERBB2 amplification in 
breast cancer patients [3,12]. Importantly, analysis of data 
from the TCGA database showed that TRAF4 gene amplifi- 
cation was also found in many other types of cancer, such as  
 
 
Figure 1  Representative structures of the tumor-necrosis factor receptor 
(TNFR)-associated factor (TRAF) family member TRAF4 and TRAF6. A 
RING finger domain in the N-terminal, a zinc finger motif and a car-
boxy-terminal TRAF domain are shown in different grey scale. 
bladder urothelial carcinoma and ovarian cancer, suggesting 
that TRAF4 is oncogenic and its possible role is not limited 
to breast cancer [3]. The pro-oncogenic role of TRAF4 is 
linked to the altering of cell mobility since the TRAF4-  
deficient mice showed impaired neural tube closure and 
tracheal ring disruption, both of which are closely associat-
ed with abnormal cell migration [8,9]. 
3  TGF-, a master regulator of breast cancer 
metastasis 
Cancer is a complex disease with multiple cellular signaling 
pathways that are cross-regulated. TGF-β signaling is tumor 
suppressive in the pre-malignant stage but contributes to 
malignant cancer progression by serving as a strong driving 
force for cancer metastasis [13,14]. Type II and type I ser-
ine/threonine kinase receptors (TβRII and TβRI, respec-
tively) mediate TGF-β signals. Upon binding of the TGF-β 
ligand, TβRII and TβRI form a heteromeric receptor com-
plex. Phosphorylation of TβRI by TβRII on serine and 
threonine residues in a glycine/serine-rich domain triggers 
TβRI kinase activity. The activated TβRI phosphorylates 
downstream SMAD2/SMAD3 to induce its association with 
SMAD4, which accumulates in the nucleus and regulates 
transcription [13–16]. SMAD complex-mediated transcrip-
tional induction of mesenchymal markers and pro-migratory 
genes provide the TGF- pathway with a potent role in 
driving EMT and promoting invasion and metastases in 
advanced cancers [17,18]. 
Recent discoveries have shown that activation of 
SMAD-independent pathways by TGF-β also contribute to 
the pro-oncogenic role of TGF-β in malignant tumors 
[17,19,20]. In line with this, positive effects from anti- 
TGF-β signaling therapies have been shown to reduce breast 
cancer invasion and metastasis [21–26]. Efficient TGF-β 
pathway inhibitory drugs have been developed and tested in 
preclinical studies, and some are currently in clinical trials 
showing expected results [27,28]. 
4  TRAF4 targets SMURF2 degradation and 
mediates SMAD activation by TGF- 
The pulse and duration of TGF-β signaling is mainly con-
trolled by TGF-β receptor activity. While the inhibitory 
SMAD7-SMURF2 complex targets TGF-β receptor for 
polyubiquitination and inhibits downstream SMAD activa-
tion, deubiquitinases, USP4/15, remove ubiquitin chains 
from TβRI, thus stabilizing the TGF-β receptor [2,29,30]. In 
a proteomic tandem affinity purification (TAP) screen, 
SMURF2 was identified as a strong binding partner of 
TRAF4 [3]. As a substrate, SMURF2 triggered polyubiqui-
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tination and degradation by TRAF4 [3]. Inversely, as a 
HECT domain-containing E3 ligase, SMURF2 could also 
initiate polyubiquitin conjugation on TRAF4, resulting in 
TRAF4 protein degradation via the proteasome [3] (Figure 
2A). These observations raise an interesting question as to 
when and where these two E3 ligases interact with each 
other. 
In response to TGF-β and in a time-dependent but 
SMAD7-independent manner, TRAF4 was observed to be 
recruited to the TGF-β receptor complex prior to the re-
cruitment of SMURF2 [3]. This indicates that a sequential 
binding event occurred on the TGF-β receptor; in other 
words, during TGF-β signaling, the receptor dictates transi-
ent activation (recruitment) of TRAF4 and degradation of 
SMURF2, eliminating the negative impact of SMURF2 on 
signaling, at least in the period when signaling is just initi-
ated [31]. Evidence shows that the receptor-TRAF4 associ-
ation precedes SMURF2 recruitment, and receptor-bound 
TRAF4 actively ubiquitylates and degrades SMURF2 [3,31]. 
Biotin could be used to label the TGF-β receptor largely on 
the cell membrane, thus streptavidin beads could allow for 
the pull-down of the active membrane-located TGF-β re-
ceptor. It has been noted that TRAF4 action on (eliminating) 
SMURF2 could positively impact active TβRI levels [3]. 
Consistently, TRAF4-deficient mouse embryonic fibro-
blasts appear less responsive to TGF-β as a readout of 
SMAD activation [3]. Therefore, elimination of SMURF2 
by TRAF4 apparently contributes to TGF-β receptor stabil-




Figure 2 (color online)  A, TRAF4 targets SMURF2 and is targeted by 
SMURF2 for proteasomal degradation. B, TRAF4-involved regulation of 
transforming growth factor (TGF)-β/SMAD (SMA- and MAD-related 
protein) signaling and SMAD-independent signaling in cancer progression. 
5  TRAF4 stimulates TAK1-mediated activation 
of non-SMAD TGF- signaling 
In response to TGF-β stimulation, TβRI-associated TRAF4 
protein rapidly undergoes degradation-independent ubiqui-
tination in which the K63-linked polyubiquitin chain is 
clearly identified [3]. This in turn stimulates TAK1 (and 
p-TAK1), a ubiquitin-dependent kinase that is also activated 
by other TRAF family members [32–35]. Similar to the 
actions of other TRAF members and distinctly in response 
to the TGF-β receptor but not TNFR, K63-polyubiquitina- 
tion of TRAF4 recruits/activates TAB-TAK1 [3], a protein 
kinase that stimulates activity of MKK and IKK. These lat-
ter two kinases can activate the p38 kinase/JNK kinase and 
NFB pathways for multiple downstream readouts [32] 
(Figure 2B); consistently, gathered evidence from TRAF4 
depleted cells suggests an impaired p38/NFB activation by 
TGF-β [3]. Therefore, TRAF4 mediates TAK1-dependent 
non-SMAD TGF-β signaling (Figure 2B). 
6  TRAF4 contributes to breast cancer metastasis 
Influenced by stromal cells, primary tumor cells undergo 
EMT or use other means to invade the circulation and be-
come circulating tumor cells (CTCs) [36]. CTCs are pro-
tected by platelets and further undergo EMT due to TGF-β 
signaling. Tumor-derived factors and exosomes mobilize 
bone marrow-derived cells to form a pre-metastatic niche to 
promote the seeding and expansion of metastasis and stro-
mal components at the metastasis niches that enhance tumor 
survival, stemness and immune evasion [37]. In epitheli-
al-like breast cancer cells, TRAF4 depletion impaired EMT, 
and in mesenchymal-like cells, TRAF4 depletion led to loss 
of cell mobility. Consistently, TRAF4-deficient cells exhib-
ited enhanced cell-cell adherence and reduced cell migrato-
ry capacity; importantly, in vivo analysis showed a loss of 
metastasis upon TRAF4 depletion in zebrafish and mice 
xenograft models that were dependent on TGF-β receptor 
signaling [3]. Additionally, SMURF1-mediated lysine 190 
ubiquitination of TRAF4 is thought to target TRAF4 to 
tight-junctions, where TRAF4 was recently proven to inter-
act with phosphoinositides (PIPs) to increase cell mobility 
[38,39]. 
7  TRAF4 correlates with poor prognosis in 
breast cancer patients 
In line with the TRAF4 gene amplification and the function 
of TRAF4 in driving breast cancer metastasis, TRAF4 lev-
els correlated with both SMAD and TAK1 activation and 
poor prognosis, as observed in over 500 breast cancer pa-
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Figure 3  Kaplan-Meier plots of disease-free survival of patients, stratified by expression of TRAF4. Data obtained from the Kaplan-Meier plotter database 
[40,41]. The P-value was calculated using a log-rank test. 
tients [3]. Analyses have suggested that high TRAF4 ex-
pression is an indicator of poor outcome in cancer patients 
[3]. Furthermore, in a broader analysis where TRAF4 level 
was examined in further detail, in which patients were strat-
ified into low (33%), middle (33%) and high (33%) expres-
sion groups, a clear trend associating TRAF4 level with 
outcome was clearly observed (Figure 3). There was appar-
ently poor disease-free survival for the middle TRAF4 level 
and an even worse outcome for patients with a high TRAF4 
level (Figure 3A). When distant metastasis-free survival 
was taken into account, a similar statistically significant 
trend was also apparent when patients were divided into the 
same TRAF4 expression groups as above (Figure 3B and 
3C). Taken together with all the biochemical findings and 
clinical analyses, the results demonstrate that TRAF4 could 
be regarded as a biomarker for a subset of breast cancer 
patients, for which anti-TGF-β therapy might be effective. 
8  Conclusion 
As a more distant member of the TRAF family, TRAF4 has 
not been linked to TNF receptor or Toll-like receptor func-
tion. It was recently found to promote signaling of the 
TGF-β family by associating with the TGF-β receptor and 
antagonizing SMURF2 function as an amplified gene in 
breast cancer. As E3 ligase activity is druggable, both in 
vitro and in vivo evidence has exposed TFAF4 as a putative 
biomarker for malignant breast cancer progression and a 
possible therapeutic target. 
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